The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE study.
 
Junichi Matsubara
Honoraria - DAIICHI SANKYO COMPANY, LIMITED
 
Kazuki Sudo
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Janssen; MSD; Nihon Medi-Physics; Pfizer
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Gilead Sciences; Loxo/Lilly; Merck; NanoCarrier; Pfizer; PRA Health Sciences; Takeda
 
Kenji Tsuchihashi
Honoraria - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma
 
Ichiro Kinoshita
Honoraria - Bayer; Chugai Pharma; Guardant Health; Konica Minolta; MSD; Novartis; Pfizer; Takeda
Research Funding - Daiich Sankyo; Eisai; Konica Minolta
 
Masanobu Takahashi
Speakers' Bureau - Bristol-Myers Squibb Japan; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yohei Chiba
No Relationships to Disclose
 
Shinji Kohsaka
Research Funding - Boehringer Ingelheim (Inst); CMIC (Inst); Eisai (Inst); H.U. Group Research Institute (Inst); Konica Minolta (Inst)
 
Ryo Sadachi
No Relationships to Disclose
 
Ryunosuke Machida
No Relationships to Disclose
 
Masahiko Ichimura
No Relationships to Disclose
 
Hitomi Okuma
No Relationships to Disclose
 
Kenta Anjo
Employment - Abbvie (I)
 
Kazumi Kurishita
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; EP biopharma; Haihe Pharmaceutical; Henlius; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Masamichi Takahashi
Speakers' Bureau - Daiichi Sankyo/UCB Japan; Novocure
Research Funding - Eisai (Inst)